SG11201805828YA - Method of treating c3 glomerulopathy - Google Patents

Method of treating c3 glomerulopathy

Info

Publication number
SG11201805828YA
SG11201805828YA SG11201805828YA SG11201805828YA SG11201805828YA SG 11201805828Y A SG11201805828Y A SG 11201805828YA SG 11201805828Y A SG11201805828Y A SG 11201805828YA SG 11201805828Y A SG11201805828Y A SG 11201805828YA SG 11201805828Y A SG11201805828Y A SG 11201805828YA
Authority
SG
Singapore
Prior art keywords
international
january
pct
months
glomerulopathy
Prior art date
Application number
SG11201805828YA
Inventor
Petrus Bekker
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11201805828YA publication Critical patent/SG11201805828YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization MD 110111101110101011111 HO 11111011101110111111111011111111101111011# International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/123716 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) (74) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/551 (2006.01) A61K 31/517 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/013132 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 12 January 2017 (12.01.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Priority Data: ZA, ZM, ZW. 62/278,788 14 January 2016 (14.01.2016) US 62/280,346 19 January 2016 (19.01.2016) US (84) Designated States (unless otherwise indicated, for every 62/347,450 8 June 2016 (08.06.2016) US kind of regional protection available): ARIPO (BW, GH, 62/397,527 21 September 2016 (21.09.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Applicant: CHEMOCENTRYX, INC. [US/US]; 850 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Maude Avenue, Mountain View, CA 94043 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Inventor: BEKKER, Petrus; 24 Coronado Avenue, Los LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Altos, CA 94022 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Agents: KEZER, William, B. et al.; Mintz Levin Cohn Published: Ferris Glovsky and Popeo, P.C., One Financial Center, Bo- ston, MA 02111 (US). — with international search report (Art. 21(3)) — = — = = (54) Title: METHOD OF TREATING C3 GLOMERULOPATHY Figure 1 represents eGFR ml/min/1.73m2 90 80 70 60 50 40 30 20 10 0 the patient's Estimated glomerular before and after treatment with compound compound filtration rate (eGFR) 1. 1 = = = = _ = = = = — _ 1-1 1-1 IN en ei 1-1 IN 1-1 (57) 0 man ei : Methods of treating a human an effective amount of a C5aR antagonist are provided. I I I I 14 month 8 months 2 months 4 months pre pre pre post Treatment suffering from or susceptible to C3 glomerulopathy comprising administering to the hu - 0
SG11201805828YA 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy SG11201805828YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US201662397527P 2016-09-21 2016-09-21
PCT/US2017/013132 WO2017123716A1 (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Publications (1)

Publication Number Publication Date
SG11201805828YA true SG11201805828YA (en) 2018-08-30

Family

ID=59312069

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805828YA SG11201805828YA (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Country Status (17)

Country Link
US (3) US20170202821A1 (en)
EP (1) EP3402486A4 (en)
JP (3) JP7339733B2 (en)
KR (1) KR20180102642A (en)
CN (1) CN108601790A (en)
AU (1) AU2017207359C1 (en)
BR (2) BR112018014222A2 (en)
CA (1) CA3010735C (en)
IL (1) IL260539B (en)
MA (1) MA43872A (en)
MX (2) MX2022006069A (en)
NZ (1) NZ744083A (en)
RU (1) RU2742888C2 (en)
SG (1) SG11201805828YA (en)
TW (1) TWI791423B (en)
WO (1) WO2017123716A1 (en)
ZA (1) ZA201804513B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445515B2 (en) 2008-12-22 2013-05-21 Chemocentryx, Inc. C5aR antagonists
RS56332B1 (en) 2010-06-24 2017-12-29 Chemocentryx Inc C5ar antagonists
ES2926828T3 (en) 2014-09-29 2022-10-28 Chemocentryx Inc Processes and intermediates in the preparation of C5aR antagonists
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
BR112018014222A2 (en) 2016-01-14 2018-12-11 Chemocentryx, Inc. c3 glomerulopathy treatment method
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
JP7133561B2 (en) 2017-03-01 2022-09-08 アキリオン ファーマシューティカルズ，インコーポレーテッド Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
EP3658657A1 (en) * 2017-07-27 2020-06-03 Procter & Gamble International Operations SA. Phase-stable, sprayable freshening compositions comprising suspended particles
EP3814374A4 (en) * 2018-05-25 2022-03-09 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
EP3856164A4 (en) 2018-09-25 2022-07-13 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
SG11202105572UA (en) 2018-11-30 2021-06-29 Chemocentryx Inc Capsule formulations
CA3179156A1 (en) * 2020-08-07 2022-02-10 Kira Pharmaceuticals (Suzhou) Ltd. Compounds as c5ar inhibitors
CA3205474A1 (en) * 2020-12-21 2022-06-30 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
CN115192563B (en) * 2022-05-09 2023-10-13 北京大学第一医院 Use of C3a/C3aR pathway antagonists for the treatment of primary membranous nephropathy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
JP2002523448A (en) 1998-08-28 2002-07-30 サイオス インコーポレイテッド Inhibitors of p38-α kinase
RU2197288C2 (en) * 1999-08-03 2003-01-27 Тверская медицинская академия Method for treating patients for chronic glomerulonephritis
JP2003532726A (en) 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション New anti-infective drug
WO2002014265A1 (en) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Novel 3-substituted urea derivatives and medicinal use thereof
AU2001288045A1 (en) 2000-09-14 2002-03-26 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof ugs
YU23503A (en) 2000-09-29 2006-03-03 Neurogen Corporation High afinity small molecule c5a receptor modulators
CA2457461C (en) 2001-08-17 2013-12-24 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
AU2002337499B2 (en) 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
ITMI20012025A1 (en) 2001-09-28 2003-03-28 Dompe Spa QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
WO2003082826A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003220553A1 (en) 2002-03-29 2003-10-20 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP1529046A1 (en) 2002-08-08 2005-05-11 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
FR2846654A1 (en) 2002-11-05 2004-05-07 Servier Lab New dihydro-4(1H)-pyridinone derivatives are useful in the treatment of cognitive disorders, neurodegenerative diseases and pain
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
ATE552253T1 (en) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-SUBSTITUTED-6-ARYL-PYRIDINE DERIVATIVES AS LIGANDS FOR C5A RECEPTORS
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP2008504275A (en) 2004-06-24 2008-02-14 インサイト・コーポレイション N-substituted piperidines and their use as pharmaceuticals
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006087543A1 (en) 2005-02-18 2006-08-24 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
DK1951663T3 (en) 2005-11-24 2016-10-10 Dompé Farm S P A (r)-arylkylaminoderivater og farmaceutiske sammensætninger indeholdende dem
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US8198266B2 (en) * 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
BRPI0812997A2 (en) 2007-06-29 2014-12-23 Torrent Pharmaceuticals Ltd New Piperidones Replaced as HSP Inducers
WO2010019210A2 (en) 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
EP3101031A1 (en) 2008-11-10 2016-12-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US8445515B2 (en) 2008-12-22 2013-05-21 Chemocentryx, Inc. C5aR antagonists
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
RS56332B1 (en) * 2010-06-24 2017-12-29 Chemocentryx Inc C5ar antagonists
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
BR112014031375A2 (en) * 2012-06-20 2017-06-27 Novartis Ag modulators of the complementary reaction series and uses thereof
CN105392803B (en) 2013-05-08 2019-12-06 诺和诺德股份有限公司 Use of C5aR antagonists
ES2926828T3 (en) 2014-09-29 2022-10-28 Chemocentryx Inc Processes and intermediates in the preparation of C5aR antagonists
BR112018014222A2 (en) 2016-01-14 2018-12-11 Chemocentryx, Inc. c3 glomerulopathy treatment method
MX2018011831A (en) 2016-04-04 2019-02-13 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS.
CA3205474A1 (en) 2020-12-21 2022-06-30 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor

Also Published As

Publication number Publication date
EP3402486A4 (en) 2019-08-28
MX2022006069A (en) 2023-01-12
WO2017123716A1 (en) 2017-07-20
JP2021183625A (en) 2021-12-02
KR20180102642A (en) 2018-09-17
JP2019501935A (en) 2019-01-24
US11779576B2 (en) 2023-10-10
JP7339733B2 (en) 2023-09-06
BR122024002810A2 (en) 2024-03-12
BR112018014222A2 (en) 2018-12-11
TWI791423B (en) 2023-02-11
CN108601790A (en) 2018-09-28
IL260539B (en) 2021-05-31
TW201726134A (en) 2017-08-01
AU2017207359A1 (en) 2018-07-26
ZA201804513B (en) 2024-01-31
US20220354837A1 (en) 2022-11-10
RU2742888C2 (en) 2021-02-11
US11285138B2 (en) 2022-03-29
JP2023126235A (en) 2023-09-07
AU2017207359B2 (en) 2022-04-14
CA3010735A1 (en) 2017-07-20
US20170202821A1 (en) 2017-07-20
RU2018129378A (en) 2020-02-14
AU2017207359C1 (en) 2022-09-01
NZ744083A (en) 2022-07-01
MA43872A (en) 2021-05-19
US20190201388A1 (en) 2019-07-04
CA3010735C (en) 2023-06-13
RU2018129378A3 (en) 2020-05-20
MX2018008624A (en) 2018-12-10
EP3402486A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201805072PA (en) Nicotine powder delivery system
SG11201808125RA (en) Methods for solid tumor treatment
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201805579SA (en) Recombinant igg fc multimers
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201809527UA (en) Methods of treating circadian rhythm sleep disorders
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases